TreatmentTrends: Psoriasis (EU) will cover practice dynamics, current use and future use projections for key products, perceived product ad-vantages and disadvantages. While the report does cover…
The hospital-treated methicillin-resistant Staphylococcus aureus (MRSA) infection market is dominated by generic vancomycin because of its low cost, physician familiarity and relatively high…
This report provides detailed analysis of the current and projected mar-kets for diabetic retinopathy (DR) and diabetic macular edema (DME). The DR population represents more than 5.8 million…
To view the recording from our webinar series, please select the video link to the left Outline – Background – Overarching theme of the EGA conference – Current and future startegies to drive…
Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy? Although several effective anti-inflammatory agents and…
Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Pulmonologists and Payers Expect of an Emerging Therapy? Although several effective anti-inflammatory agents and…
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…
Opportunity Awaits Therapies Offering Improvements in Efficacy and Safety over Currently Available TNF-Alpha Inhibitors The availability of tumor necrosis factor alpha (TNF-α) inhibitors as…
Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…
Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…
Although the postoperative pain market is sizeable in terms of both dollars and the potential patient pool, treatment is very fragmented, with many drugs and formulations available within each drug…
LaunchTrends: Gilotrif is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Gilotrif (Boehringer Ingelheim’s afatinib)…
Gauging Physicians’ and Payers’ Evolving Receptivity to Emerging Symptomatic vs. Disease-Modifying Therapies With aging populations, the seven major pharmaceutical markets face an ever-…
Gauging Physicians’ and Payers’ Evolving Receptivity to Emerging Symptomatic vs. Disease-Modifying Therapies With aging populations, the seven major pharmaceutical markets face an ever-…
Based on a survey of 100 medical oncologists and 30 MCO pharmacy and medical directors, this report explores the market access challenges facing key current and emerging brands used in the…